Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
LeiomyosarcomaUterine Neoplasm
Interventions
DRUG

gemcitabine, docetaxel, doxorubicin

Cycles = 28 days

Trial Locations (12)

10021

Memorial Sloan Kettering Cancer Center, New York

19106

Pennsylvania Oncology Hematology Associates, Philadelphia

20010

Washington Cancer Institute/Washington Hospital Center (Medstar), Washington D.C.

30308

Winship Cancer Institute at Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

46260

St. Vincent Gynecologic Oncology, Indianapolis

48109

University of Michigan, Ann Arbor

60637

University of Chicago, Chicago

68114

Nebraska Methodist Hospital, Omaha

77030

MD Anderson Cancer Center, Houston

01225

Dana Farber Cancer Institute, Boston

02114

Massachusetts General, Boston

All Listed Sponsors
lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT00282087 - Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma | Biotech Hunter | Biotech Hunter